Hua Medicine Ltd.

As of December 31, 2025, Hua Medicine Ltd. carries a market capitalization of 3.07B, placing it among publicly traded companies globally. Its enterprise value stands at 2.19B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hua Medicine Ltd.'s next confirmed earnings release is scheduled for April 1, 2027.

As of December 31, 2025, Hua Medicine Ltd. has 996.52M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Hua Medicine Ltd. maintains a current ratio of 6.17, meaning it holds 6.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Hua Medicine Ltd.'s stock has declined approximately 38.43% over the past 52 weeks. The 50-day moving average sits at 2.39, while the 200-day moving average is 2.83.

As of December 31, 2025, Hua Medicine Ltd. holds 1.22B in cash and equivalents against 335.73M in total debt, resulting in a net debt position of -936.08M. Total book value stands at 1.12B, with working capital of 1.21B providing operational flexibility.